【04/30更新】(株)ジーエヌアイグループ【2160】は一体どこまで下がるのか。これからどうなる！？掲示板の反応まとめ。

３連チャンストップ高を見てみたい。

S高だだだだだ。。。。。。。。

出ましたか。。。。。

ホルダーおめでとうございます。

でで出ましたね

待ちに待ったビッグIRか？

いいね‼️

まあ、もう売る人はいないだろ

？
はぁ
古いメディアですか
確かに
過去の事ですから
未来志向の人なら
買い残と貸し株と出来高の動きは気になるのかも？？
参加者＆出来高は

連日閑古鳥相場です
4月は一月間
私も記憶にありません
非常に珍しい連続22日間100万株割れ
4/30は「約26万株」という悲惨な状況です

欲しい人は売るしかなさそう？
ペプチの御大
詐欺内爺さんにお願いして
資産家というし、お金持ちですし？？
10億円分売ってもらえば

森君は喜びそう・・・

違うかな？？
ねぇ
空売り師森君！！

トレード数年以上やってれば判ると思うけど、
雑誌やワイドショーなどで取り上げられても、
古いメディアの影響力はほぼ皆無に近いです。
全くと言っていいほど、微動だにしませんよ。

？
どうしたん？？
先もあともない
嘘つき爺さん
何で森君にバトンタッチしたの

複判でも守備範囲違うとかな？
いいじゃん
楽しくなってきた
今後は
ノルウェーの森君
先も後も内クン
同一視にする
ヨロピクね

田んぼの肥溜めに落ちるなよ
ノルウェイの森君
ハイ
( ^)o(^ ).
そうおもう空売り講釈
確認だネ

欲ボケ金男あじいちゃん

GNIの煽りで手に入れた不動産をアップして頂戴
それにしても、多くのイナゴが金男の犠牲になったんだろうな

>>658
そんなの言うたらSHIFT700円台、レーザーテック1300円台でしばらく持ってた事有るわ。
そういえばGNIなんか11円で1万株とか持ってた事もあったな。

テスタ氏そーせいGNI全力して人生挽回

グニグイグイ

>>372
GNIでわろた

グニつよい

Magnitude 5.7 earthquake offshore Chile

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

Chinese President Xi: Instabilities And Uncertainties Of The World Have Significantly Increased - Boao Forum

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

気文2160助かりますか？お願いします

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf
https://www.axcelead-hd.com/

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

GNI↑

U.S. RECOGNIZES DEEP ECONOMIC AND COMMERCIAL TIES BETWEEN JAPAN AND CHINA AND RESPECTS SUGA'S DESIRE TO WALK A CAREFUL COURSE - OFFICIAL

グミは頑張ってるのグニと言ったら全く…

グミと間違えてグニ買ったけどこっちもこっちでひでぇ
バイオやんけ…

イメージワンはGNIを思い出す

重要な発表まで株価上げ続けて、発表でもって滝行

GNI　完全に終了

GNI　おわった

GNI↑

バブグニ悲惨やな
バブグミとバブチームもぱっとしないし、バブターツなんて出来高400株とかどうすんのよ
バブ旛くらいやん